Free Trial
NASDAQ:IDXX

IDEXX Laboratories (IDXX) Stock Price, News & Analysis

IDEXX Laboratories logo
$535.54 +1.23 (+0.23%)
Closing price 04:00 PM Eastern
Extended Trading
$535.86 +0.33 (+0.06%)
As of 05:07 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About IDEXX Laboratories Stock (NASDAQ:IDXX)

Key Stats

Today's Range
$527.81
$539.11
50-Day Range
$501.57
$573.07
52-Week Range
$356.14
$579.47
Volume
760,497 shs
Average Volume
714,639 shs
Market Capitalization
$43.07 billion
P/E Ratio
49.50
Dividend Yield
N/A
Price Target
$557.88
Consensus Rating
Moderate Buy

Company Overview

IDEXX Laboratories Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
65th Percentile Overall Score

IDXX MarketRank™: 

IDEXX Laboratories scored higher than 65% of companies evaluated by MarketBeat, and ranked 315th out of 934 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    IDEXX Laboratories has received a consensus rating of Moderate Buy. The company's average rating score is 2.78, and is based on 5 buy ratings, 3 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    IDEXX Laboratories has only been the subject of 4 research reports in the past 90 days.

  • Read more about IDEXX Laboratories' stock forecast and price target.
  • Earnings Growth

    Earnings for IDEXX Laboratories are expected to grow by 13.83% in the coming year, from $11.93 to $13.58 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of IDEXX Laboratories is 49.50, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 28.14.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of IDEXX Laboratories is 49.50, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 29.52.

  • Price to Earnings Growth Ratio

    IDEXX Laboratories has a PEG Ratio of 4.07. PEG Ratios above 1 indicate that a company could be overvalued.

  • Price to Book Value per Share Ratio

    IDEXX Laboratories has a P/B Ratio of 27.49. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about IDEXX Laboratories' valuation and earnings.
  • Percentage of Shares Shorted

    3.32% of the float of IDEXX Laboratories has been sold short.
  • Short Interest Ratio / Days to Cover

    IDEXX Laboratories has a short interest ratio ("days to cover") of 4.4.
  • Change versus previous month

    Short interest in IDEXX Laboratories has recently increased by 3.53%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    IDEXX Laboratories does not currently pay a dividend.

  • Dividend Growth

    IDEXX Laboratories does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    3.32% of the float of IDEXX Laboratories has been sold short.
  • Short Interest Ratio / Days to Cover

    IDEXX Laboratories has a short interest ratio ("days to cover") of 4.4.
  • Change versus previous month

    Short interest in IDEXX Laboratories has recently increased by 3.53%, indicating that investor sentiment is decreasing.
  • News Sentiment

    IDEXX Laboratories has a news sentiment score of 1.27. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.63 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 36 news articles for IDEXX Laboratories this week, compared to 18 articles on an average week.
  • Search Interest

    Only 4 people have searched for IDXX on MarketBeat in the last 30 days. This is a decrease of -20% compared to the previous 30 days.
  • MarketBeat Follows

    6 people have added IDEXX Laboratories to their MarketBeat watchlist in the last 30 days. This is an increase of 500% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, IDEXX Laboratories insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,182,920.00 in company stock.

  • Percentage Held by Insiders

    Only 0.98% of the stock of IDEXX Laboratories is held by insiders.

  • Percentage Held by Institutions

    87.84% of the stock of IDEXX Laboratories is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about IDEXX Laboratories' insider trading history.
Receive IDXX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for IDEXX Laboratories and its competitors with MarketBeat's FREE daily newsletter.

IDXX Stock News Headlines

Earnings Outlook For IDEXX Laboratories
IDEXX Laboratories Q2 2025 Earnings Preview
One stock to replace Nvidia
I'm a Futurist: Here are 3 stocks better than Nvidia Nvidia's own customers could soon become fierce competitors, dethroning the AI Chip King. But there's a critical component that AI data centers need just as badly as chips. The demand is so massive that a single data center uses enough of it to stretch around the earth eight times. While the media hypes up AI chips, the smart money has found the next big thing. Discover Futurist Eric Fry's "Nvidia-killer" stock ideas.
IDEXX Laboratories, Inc. (IDXX): A Bull Case Theory
See More Headlines

IDXX Stock Analysis - Frequently Asked Questions

IDEXX Laboratories' stock was trading at $413.44 at the beginning of the year. Since then, IDXX shares have increased by 29.5% and is now trading at $535.54.

IDEXX Laboratories, Inc. (NASDAQ:IDXX) posted its quarterly earnings results on Thursday, May, 1st. The company reported $2.96 EPS for the quarter, beating the consensus estimate of $2.93 by $0.03. The business's revenue for the quarter was up 3.6% on a year-over-year basis.
Read the conference call transcript
.

IDEXX Laboratories' top institutional shareholders include Blair William & Co. IL (1.34%), William Blair Investment Management LLC (0.85%), Montrusco Bolton Investments Inc. (0.53%) and Vontobel Holding Ltd. (0.51%). Insiders that own company stock include Jonathan W Ayers, Jonathan Jay Mazelsky, Brian P Mckeon, James F Polewaczyk, George Fennell, Kathy V Turner, Michael Lane, Daniel M Junius, Sophie V Vandebroek, M Anne Szostak and Bruce L Claflin.
View institutional ownership trends
.

Shares of IDXX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that IDEXX Laboratories investors own include Tesla (TSLA), Broadcom (AVGO), Applied Materials (AMAT), HubSpot (HUBS), ASML (ASML), CrowdStrike (CRWD) and Cadence Design Systems (CDNS).

Company Calendar

Last Earnings
5/01/2025
Today
8/01/2025
Next Earnings (Confirmed)
8/04/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED INSTRUMENTS
Sub-Industry
Health Care Equipment
Current Symbol
NASDAQ:IDXX
CIK
874716
Employees
11,000
Year Founded
1983

Price Target and Rating

High Price Target
$625.00
Low Price Target
$510.00
Potential Upside/Downside
+4.4%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.78
Research Coverage
9 Analysts

Profitability

EPS (Trailing Twelve Months)
$10.82
Trailing P/E Ratio
49.38
Forward P/E Ratio
44.79
P/E Growth
4.07
Net Income
$887.87 million
Net Margins
22.76%
Pretax Margin
28.60%
Return on Equity
57.35%
Return on Assets
26.97%

Debt

Debt-to-Equity Ratio
0.31
Current Ratio
1.16
Quick Ratio
0.81

Sales & Book Value

Annual Sales
$3.90 billion
Price / Sales
11.02
Cash Flow
$11.61 per share
Price / Cash Flow
46.03
Book Value
$19.48 per share
Price / Book
27.43

Miscellaneous

Outstanding Shares
80,420,000
Free Float
79,634,000
Market Cap
$42.97 billion
Optionable
Optionable
Beta
1.54

Social Links

 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

This page (NASDAQ:IDXX) was last updated on 8/1/2025 by MarketBeat.com Staff
From Our Partners